Bimodal expression of potential drug target CLL- 1 (CLEC12A) on CD34+ blasts of AML patients

Myeloid neoplasms in pretreated patients with CLL are defined as late complication of cytotoxic chemotherapy or radiotherapy by WHO Classification of Hematologic malignancies

Results of a phase 1 study of quizartinib (AC220) as maintenance therapy in subjects with acute myeloid leukemia in remission following allogeneic hematopoietic cell

In this issue of Blood, Marlein et al 1 identify a tumor-speci fi c NOX2-dependent transfer of mitochondria from bone marrow stromal cells (BMSCs) to acute myeloid leukemia (AML)

In other words, the amount of residual disease measured depends on who measured it (ie, method used, ex- perience of the operator), how MRD levels are reported (percentage of

Ando og medarbeidere (1) har vist at CD34-negative celler fra navlestrengsblod kan danne store mengder CD34-positive celler med stamcelleegenskaper in vitro.. Arbeidet beskriver en

The safety and efficacy of ibrutinib (420 mg) in chronic lymphocytic leukemia (CLL) were evaluated in a phase 2 study; 51 patients had TP53 aberration (TP53 cohort) and 35 were

LM, FLT3 length mutation; M, NPM1 mutation; ND, not determined, Chemo, Chemotherapy consisted of three days with idarubicin (I) or daunorubicin (D), and concomitantly start up

Valproic acid in combination with all-trans retinoic acid and intensive induction therapy for acute myeloid leukemia in older patients. Mechanism of action of